<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03036293</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-TN-001</org_study_id>
    <nct_id>NCT03036293</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Tenoten® in the Treatment of Anxiety in Patients With Somatoform, Stress-related and Other Neurotic Disorders</brief_title>
  <official_title>International Multicenter, Double-blind, Randomized Parallel Group Placebo-controlled Clinical Trial of Efficacy and Safety of Different Dosing Regimens of Tenoten® in the Treatment of Anxiety in Patients With Somatoform, Stress-related and Other Neurotic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are:

        -  To further examine the efficacy and safety of Tenoten® in the treatment of anxiety in
           patients with somatoform, stress-related and other neurotic disorders.

        -  To compare the efficacy of two dosing regimens of Tenoten® (4 tablets daily vs.8 tablets
           daily, both for 12 weeks) in the treatment of anxiety in patients with somatoform,
           stress-related and other neurotic disorders.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the mean HAM-A score at 12 weeks of treatment in patients from: 1. Group 1 (Tenoten®, 4 tablets a day); 2. Group 3 (Tenoten®, 8 tablets a day).</measure>
    <time_frame>12 weeks</time_frame>
    <description>HAM-A</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the mean HAM-A score at 4 weeks of treatment in patients from: 1.1. Group 1 (Tenoten®, 4 tablets a day); 1.2. Group 3 (Tenoten®, 8 tablets a day).</measure>
    <time_frame>4 weeks</time_frame>
    <description>HAM-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean HAM-A score at 8 weeks of treatment versus baseline in patients from: 2.1. Group 1 (Tenoten®, 4 tablets a day); 2.2. Group 3 (Tenoten®, 8 tablets a day).</measure>
    <time_frame>8 weeks</time_frame>
    <description>HAM-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving at least a 50% improvement in the HAM-A score from baseline in: 3.1. Group 1 (Tenoten®, 4 tablets a day) 3.1.1. at 4 weeks; 3.1.2. at 8 weeks; 3.1.3. at 12 weeks; 3.2. Group 3 (Tenoten®, 8 tablets a day) 3.2.1. at</measure>
    <time_frame>4,8,12 weeks</time_frame>
    <description>HAM-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with no anxiety (HAM-A score &lt;14) in: 4.1. Group 1 (Tenoten®, 4 tablets a day) 4.1.1. at 4 weeks; 4.1.2. at 8 weeks; 4.1.3. at 12 weeks;</measure>
    <time_frame>4,8,12 weeks</time_frame>
    <description>HAM-A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the total EQ-5D-3L score at 12 weeks of treatment in patients from: 5.1. Group 1 (Tenoten®, 4 tablets a day); 5.2. Group 3 (Tenoten®, 8 tablets a day).</measure>
    <time_frame>12 weeks</time_frame>
    <description>EQ-5D-3L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total CGI scores in patients from: 6.1. Group 1 (Tenoten®, 4 tablets a day); 6.2. Group 3 (Tenoten®, 8 tablets a day).</measure>
    <time_frame>12 weeks</time_frame>
    <description>CGI</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Tenoten, 2 tablets twice a day (4 tablets a day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, 2 tablets twice a day (4 tablets a day)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenoten, 2 tablets 4 times daily (8 tablets a day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, 2 tablets 4 times daily (8 tablets a day)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenoten</intervention_name>
    <description>Safety and Efficiency</description>
    <arm_group_label>Tenoten, 2 tablets twice a day (4 tablets a day)</arm_group_label>
    <arm_group_label>Tenoten, 2 tablets 4 times daily (8 tablets a day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Safety and Efficiency</description>
    <arm_group_label>Placebo, 2 tablets twice a day (4 tablets a day)</arm_group_label>
    <arm_group_label>Placebo, 2 tablets 4 times daily (8 tablets a day)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients of both sexes aged 18-45 years inclusively.

          2. Patients diagnosed with somatoform, stress-related, and other neurotic disorders (F43,
             F45, and F48) , in accordance with the ICD-10 criteria.

          3. A moderate and severe anxiety (HADS score ≥ 11) documented at screening.

          4. Patients providing signed Informed Consent form for participation in the clinical
             trial.

          5. Patients of reproductive age (of both sexes) using contraceptives and contraceptive
             methods during the study and for 30 days after the end of participation in the trial.

        Exclusion Criteria:

          1. Moderate and severe depression symptoms recorded at screening (HADS score ≥ 11).

          2. Organic, including symptomatic, mental disorders (F00-09).

          3. Mental and behavioural disorders due to psychoactive substance use (F10-19).

          4. Schizophrenia, schizotypal and delusional disorders (F20-29).

          5. Mood [affective] disorders(F30-39).

          6. Phobic (F40) and other anxiety disorders (F41), obsessive-compulsive disorder (F42),
             dissociative [conversion] disorders (F44), depersonalization-derealization syndrome
             (F48.1).

          7. Behavioral syndromes associated with physiological disturbances and physical factors
             (F50-59).

          8. Disorders of adult personality and behavior (F60-69).

          9. Intellectual disabilities (F70-79).

         10. Inflammatory and traumatic brain injuries with permanent neurological deficit.

         11. Prior diagnosis of a class III or IV cardiovascular disease (according to the New York
             Heart Association, 1964)

         12. Malignant neoplasms/suspected malignant neoplasms.

         13. An allergy/intolerance to any of the components of medications used in the treatment.

         14. Malabsorption syndrome (including hereditary or acquired lactase or other
             disaccharidase deficiency) and galactosemia.

         15. Any conditions that, from investigator's point of view, may affect the patient's
             ability to participate in the trial.

         16. Hospitalizations or surgeries scheduled for any date during the participation in the
             study.

         17. Patients who, from investigator's point of view, will fail to comply with the
             observation requirements of the trial or with the dosing regimen of the study drugs.

         18. Use of drugs listed in &quot;Prohibited drugs&quot; within a month prior to enrollment.

         19. Drug addiction, alcohol use in the amount over 2 units of alcohol a day.

         20. Pregnant or breast-feeding women.

         21. Participation in other clinical trials within 3 month prior to the enrollment in this
             study.

         22. Patients are related to the research personnel of the investigative site who are
             directly involved in the trial, or patients who are the immediate family member of the
             researcher. The 'immediate family member' includes husband/wife, parents, children or
             brothers (or sisters), regardless of whether they are natural or adopted.

         23. Patients works for OOO &quot;NPF &quot;MATERIA MEDICA HOLDING&quot;, i.e. is the company's employee,
             temporary contract worker, or appointed official responsible for carrying out the
             research (or the immediate relative).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mikhail Putilovskiy, MD</last_name>
    <phone>+74952761571</phone>
    <phone_ext>302</phone_ext>
    <email>PutilovskiyMA@materiamedica.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kazakh National Medical University named after S.D. Asfendiyarov</name>
      <address>
        <city>Almaty</city>
        <zip>050000</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saltanat Kamenova, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Saltanat Kamenova, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South - Kazakhstan State Pharmaceutical Academy</name>
      <address>
        <city>Shymkent</city>
        <zip>160019</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gulsum Duchshanova, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Gulsum Duchshanova, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Autonomous Healthcare Institution Order of the Red Banner of Labor City Clinical Hospital No. 1</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galina Belskaya, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Galina Belskaya, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Kazan Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Kazan'</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enver Bogdanov, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Enver Bogdanov, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The State Autonomic Health Care institution &quot;Interregional clinical and diagnostical center&quot;</name>
      <address>
        <city>Kazan'</city>
        <zip>420101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina Hasanova, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Dina Hasanova, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LLC &quot;City Center for Neurology and Pain Management&quot;</name>
      <address>
        <city>Kazan'</city>
        <zip>420110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Mendelevich, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Elena Mendelevich, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Family policlinic no. 4&quot;</name>
      <address>
        <city>Korolev</city>
        <zip>141060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantin Glushkov, MD</last_name>
    </contact>
    <investigator>
      <last_name>Konstantin Glushkov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Budget Health Care institution of Moscow the City &quot;Scientific and practical psychoneurological center n.a. Z.P. Solovyov&quot; of the Administration of Health Care of Moscow City</name>
      <address>
        <city>Moscow</city>
        <zip>115419</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alla Gecht, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Alla Gecht, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The State Budget Health Care institution of Moscow the City &quot;City clinical hospital No. 12 of the Administration of Health Care of Moscow City&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115516</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Kamchatnov, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Pavel Kamchatnov, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pirogov Russian National Research Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgenij Gusev, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Evgenij Gusev, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The State Budget Educational institution of High Professional Training I.M. Sechenov First Moscow State Medical University of Ministry of Health Care of the Russian Federation, Hospital of nervous diseases A.Y. Kozhevnikov</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Parfenov, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Vladimir Parfenov, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State budgetary institution of public health services of the Nizhniy Novgorod region &quot;Nizhegorod Regional Clinical Hospital named after NA Semashko&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandr Gustov, MD, PhD, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Alexandr Gustov, MD, PhD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LLC &quot;City Neurological Center&quot; Sibneyromed &quot;</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Pavlov First Saint Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandr Amelin, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Aleksandr Amelin, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pavlov First Saint Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgenij Barantsevich, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Evgenij Barantsevich, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State-Funded Healthcare Institution of the Samara Region &quot;Samara City N.I. Pirogov Clinical Hospital №1&quot;</name>
      <address>
        <city>Samara</city>
        <zip>443096</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Lokshtanova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tatyana Lokshtanova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University named after V. I. Razumovsky</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oleg Kolokolov, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Oleg Kolokolov, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The State Budget Educational institution of High Professional Training Smolensk State Medical University of Ministry of Health Care of the Russian Federation, Smolensk regional clinical hospital</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalya Maslova, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Natalya Maslova, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The state budgetary health care institution of the Vladimir region &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuliya Gerasimova, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yuliya Gerasimova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Volgograd State Medical University</name>
      <address>
        <city>Volgograd</city>
        <zip>400131</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Kurushina, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Olga Kurushina, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The State Health Care Institution Yaroslavl region &quot;Clinical Hospital №8</name>
      <address>
        <city>Yaroslavl'</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalya Pizova, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Natalya Pizova, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>State Institution of Health of the Yaroslavl Region Clinical Hospital No. 8</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandr Malygin, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Alexandr Malygin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2017</study_first_submitted>
  <study_first_submitted_qc>January 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2017</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Neurotic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

